Medjet
This article was originally published in The Gray Sheet
Executive Summary
Strategic alternatives under consideration by the ophthalmic device maker include sale of the company, one or more joint ventures, a merger or restructuring. Edison, New Jersey-based Medjet's first commercial product, the HydroBrush water jet-based keratome for ophthalmic epithelium removal, was 510(k) cleared in January 1998 (1"The Gray Sheet" Feb. 16, 1998, I&W-8). A new water jet microkeratome under development "is working well, and its advantages for use in refractive surgery have been evident to surgeons that have used it," Chairman Eugene Gordon says in a release. "We believe that exploring strategic options may hasten its introduction and help Medjet's common stock to more accurately reflect the quality of its technology"
You may also be interested in...
Medjet may seek marketing partner for recently cleared HydroBrush keratome device.
MEDJET MAY SEEK HYDROBRUSH KERATOME MARKETING PARTNER following 510(k) clearance for the ophthalmic epithelium removal product on Jan. 23, the company says. While marketing plans for the HydroBrush have not been finalized, Medjet anticipates a price of between $5,000-10,000 for the system.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.